RAPT - RAPT Therapeutics, Inc.
IEX Last Trade
1.945
-0.055 -2.828%
Share volume: 111,806
Last Updated: Thu 26 Dec 2024 08:30:19 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.00
-0.06
-2.75%
Fundamental analysis
19%
Profitability
3%
Dept financing
25%
Liquidity
50%
Performance
25%
Performance
5 Days
-0.57%
1 Month
54.46%
3 Months
-7.49%
6 Months
-43.28%
1 Year
-92.99%
2 Year
-89.92%
Key data
Stock price
$1.94
DAY RANGE
$1.73 - $2.08
52 WEEK RANGE
$0.85 - $27.35
52 WEEK CHANGE
-$93.21
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Brian R. Wong
Region: US
Website: rapt.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: rapt.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
RAPT Therapeutics, Inc. focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Recent news